恆地韓家輝:上半年擬推鴨(月利)洲大街及(魚則)魚涌項目 共涉逾550伙
恆基物業代理有限公司營業(二)部總經理韓家輝表示,部門上半年計劃推出恆地(00012.HK)港島區之鴨(月利)洲大街及(魚則)魚涌項目,共提供逾550個單位;下半年亦會有多個焦點新盤陸續登場,包括堅道項目,約180伙,及已成功發展多期涉約600伙的旺角利奧坊第4期。
另外,與會德豐、新世界(00017.HK)及帝國集團合作的啟德跑道區第4B區3號地盤(新九龍內地段第6574號),涉逾1,000個單位,可望於年底至2022年初推售。
他續說,去年底推售的尖沙咀項目「本木」將屆現樓,預計約本年中交樓。而「THE RICHMOND」及「藝里坊2號」亦預計最快於本年底開始交樓。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.